Evidence mapPaperPMID 12435692Full record

ArticleAntimicrobial agents and chemotherapy2002

Synthetic peptides that exert antimicrobial activities in whole blood and blood-derived matrices.

Michael R Yeaman, Kimberly D Gank, Arnold S Bayer, Eric P Brass

Open access · greenAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 90 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Identification of novel targets of azithromycin activity againstProceedings of the National Academy of Sciences of the United States of America · 2020
    Article
  12. Article
  13. Article
  14. Unifying structural signature of eukaryotic α-helical host defense peptides.Proceedings of the National Academy of Sciences of the United States of America · 2019
    Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Michael R YeamanDepartment of Medicine, Division of Infectious Diseases, Harbor-UCLA Medical Center, Research and Education Institute at Harbor-UCLA, Torrance, California 90502, USA. mryeaman@ucla.edu
Kimberly D Gank
Arnold S Bayer
Eric P Brass
University of California, Los Angeles · USOffice of Infectious Diseases · USUCLA Medical Center · US

Funding

DETERMINANTS IN PLATELET MICROBICIDAL PROTEINSR01AI048031 · LA BIOMED RES INST/ HARBOR UCLA MED CTR · 2000 to 2004
$1.6M
STAPHYLOCIDAL MECHANISM OF PLATELET MICROBICIDAL PROTEINR01AI039108 · LA BIOMED RES INST/ HARBOR UCLA MED CTR · 1997 to 2005
$1.5M
CORE FACILITY RESEARCH PEPTIDE SYNTHESIZERS10RR014857 · LA BIOMED RES INST/ HARBOR UCLA MED CTR · 2001 to 2001
$132k
NCRR NIH HHS RR14857NIAID NIH HHS AI39108NIAID NIH HHS AI48031NIAID NIH HHS R01 AI039108NIAID NIH HHS R01 AI048031
6 · The paper itself

Abstract

Peptides that exert antimicrobial activity in artificial media may lack activity within blood or other complex biological matrices. To facilitate the evaluation of antimicrobial peptides for possible therapeutic utility, an ex vivo assay was developed to assess the extent and durability of peptide antimicrobial activities in complex fluid biomatrices of whole blood, plasma, and serum compared with those in conventional media. Novel antimicrobial peptides (RP-1 and RP-11) were designed based in part on platelet microbicidal proteins. RP-1, RP-11, or gentamicin was introduced into biomatrices either coincident with, or 2 h prior to, inoculation with an Escherichia coli target organism. Antimicrobial activities of peptides were assessed by quantitative culture 2 h after bacterial inoculation and compared to those of peptide-free and gentamicin controls. In whole blood and homologous plasma or serum, introduction of RP-1 or RP-11 coincident with E. coli was associated with a significant reduction in CFU per milliliter versus the respective peptide-free controls. Moreover, substantial antimicrobial activity remained when RP-1 or RP-11 was placed into whole blood or plasma 2 h prior to E. coli inoculation. These results suggest that the peptides were not rapidly inactivated within these biomatrices. Peptide antimicrobial activities were negatively affected by preincubation in serum or in heat-inactivated serum, compared with those of the respective controls. Peptides RP-1 and RP-11 were consistently effective at lower concentrations in biomatrices than in artificial media, indicating favorable antimicrobial interactions with components of blood or blood fractions. Collectively, these findings support the concept that synthetic peptides can be designed to exert potent antimicrobial activities in relevant and complex biological matrices.

Indexed as

PeptidesAnti-Bacterial AgentsBlood Bactericidal ActivityEscherichia coliGentamicinsAnti-Bacterial AgentsGentamicinsPeptides

Identifiers

PMID12435692
PMCPMC132762
OpenAlexW2111690797

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.